Kestra Medical Technologies Reports 2026 AGM Results; PwC Ratified

What Happened

• Kestra Medical Technologies, Ltd. filed an 8-K on September 10, 2026 reporting the results of its 2026 Annual Meeting held on September 9, 2026. Shareholders elected three Class II directors—Raymond W. Cohen, Kevin Reilly and Traci S. Umberger—to serve until the 2029 annual meeting, and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending April 30, 2027. The filing was signed by Brian Webster, President and CEO.

Key Details

• Total shares voted in person or by proxy: 55,399,491, representing ~94.53% of 58,603,121 outstanding shares (record date July 17, 2026).
• Director election vote totals:
  • Raymond W. Cohen — For: 37,334,685; Against: 10,779,640; Abstain: 34,843; Broker non-vote: 7,259,323.
  • Kevin Reilly — For: 38,900,190; Against: 9,204,737; Abstain: 35,241; Broker non-vote: 7,259,323.
  • Traci S. Umberger — For: 38,866,030; Against: 9,238,943; Abstain: 35,195; Broker non-vote: 7,259,323.
• Auditor ratification vote: PricewaterhouseCoopers LLP — For: 55,356,225; Against: 8,469; Abstain: 34,797.

Why It Matters

• The election results confirm board composition and governance continuity through the 2029 annual meeting, which can affect strategic oversight and investor confidence.
• Ratification of PwC secures the company’s independent auditor for the coming fiscal year, providing continuity in external audit oversight for fiscal 2027.
• High shareholder turnout (~94.5%) indicates substantial investor participation in corporate decisions; the listed broker non-votes (7,259,323) show shares present but not voted on director elections.